Suchergebnisse - "Silva, Inês"

PubPharm (20)

1

Blockage of aquaporin-3 peroxiporin activity by organogold compounds affects melanoma cell adhesion, proliferation and migration

enthalten in: The Journal of physiology | 2024

von da Silva, I. | Pimpão, C. | Paccetti-Alves, I. | +4

2

Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma

enthalten in: Pathology | 2023

von Shteinman, E. | Vergara, I. | Rawson, R. | +8

3

Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres

enthalten in: Cancer medicine | 2023

von Brown, L. | da Silva, I. | Moujaber, T. | +5

4

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies

enthalten in: Oncoimmunology | 2023

von Gide, T. | Paver, E. | Yaseen, Z. | +7

5

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

enthalten in: Journal for immunotherapy of cancer | 2022

von Pires da Silva, I. | Zakria, D. | Ahmed, T. | +14

6

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy

enthalten in: Journal for immunotherapy of cancer | 2022

von Attrill, G. | Owen, C. | Ahmed, T. | +13

7

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma : practical guidance for the Australian setting

enthalten in: Pathology | 2022

von Scolyer, R. | Atkinson, V. | Gyorki, D. | +46

8

Causes, consequences and clinical significance of aneuploidy across melanoma subtypes

enthalten in: Frontiers in oncology | 2022

von Shteinman, E. | Wilmott, J. | da Silva, I. | +3

9

Multiomic profiling of checkpoint inhibitor-treated melanoma : Identifying predictors of response and resistance, and markers of biological discordance

enthalten in: Cancer cell | 2022

von Newell, F. | Pires da Silva, I. | Johansson, P. | +25

CommentIn: Cancer Cell. 2022 Jan 10;40(1):14-16. - PMID 35016026

10

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets

enthalten in: Cancers | 2021

von Gide, T. | Pires da Silva, I. | Quek, C. | +11